AN UNBIASED VIEW OF LDN-27219 AS A CANCER DRUG CANDIDATE

1 particularly interesting compound is LDN-27219. Though most tTG inhibitors are meant to bind to your protein crosslinking active web page, LDN-27219 in its place binds on the nucleotide binding pocket in the enzyme while it can be in its shut-condition conformation, and stabilizes that conformation to prevent crosslinking activity.78 Schneider et